Therapies for improved diseases are expected to account for 69.2% of the market.
GlobalData said the Alzheimer’s disease (AD) market is expected to reach $17B by 2033 at a CAGR of 21.8%.
The industry’s expansion is attributed to the entry of modified disease therapy (DMTS), aging population, and the entry of symptomatic treatments for AD-related agitation and psychosis.
DMT is expected to account for 69.2% of the global market by 2033.
However, the unmet need remains therapeutic visits, says Philippa Salter, a neurology analyst at GlobalData.
“The new DMT is considered only moderately efficient, so not only will it progress slowly, but it still has a great opportunity to prevent more effective DMTs from disease, and prevention is the ultimate goal,” Salter added.
8mm = United States, France, Germany, Italy, Spain, United Kingdom, Japan and China
n = f.fbq = function () n.callMethod ? n.callMethod.apply(n, arguments) : n.queue.push(arguments); ; if (! f._fbq) f._fbq = n;
n.push = n; n.loaded = !0; n.version = "2.0"; n.queue = []; t = b.createElement(e); t.async = !0; t.defer = !0; t.src = v; s = b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t, s); )(window, document, "script", "https://connect.facebook.net/en_US/fbevents.js"); fbq("init", "669684050547860"); fbq("track", "PageView"); , 5000);
